Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Zscaler Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.87 (market cap $868.62M), while Zscaler Inc trades at $177.1 (market cap $28.87B). The key difference: Zscaler Inc is far larger — about 33.2× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | ZS | |
|---|---|---|
Market Cap | $868.62M | $28.87B |
Sector | Health | Technology |
52-Week High | $30.81 | $336.27 |
52-Week Low | $16.87 | $118.05 |
Enterprise Value | $1.27B | $27.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
Zscaler (ZS) trades at $176.68, up 4.74% with strong technical momentum and bullish analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though profitability remains negative with a -2.44% net margin. Recent earnings beats and leadership in Gartner's Magic Quadrant for security platforms support positive momentum, while elevated valuation ratios (P/S 8.94, EV/EBITDA 188.83) reflect growth expectations.
Outlook remains cautiously optimistic with 79% analyst buy ratings and $191.81 consensus target, but risks include persistent unprofitability, high spending, and competitive pressures. The upcoming Q2 2026 earnings report on September 3 will be critical for validating growth trajectory amid concerns about execution and valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
